Treatment of cancer pain with transdermal fentanyl
- 1 March 2001
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 2 (3) , 165-172
- https://doi.org/10.1016/s1470-2045(00)00258-8
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Clinical Pharmacokinetics of Transdermal OpioidsClinical Pharmacokinetics, 2000
- Reproducible fentanyl doses delivered intermittently at different time intervals from an electrotransport systemJournal of Pharmaceutical Sciences, 1999
- PP13. Comparison of the cost of managing constipation in cancer patients receiving oral morphine or transdermal fentanylEuropean Journal Of Cancer, 1997
- Fentanyl Remaining in a Transdermal System Following Three Days of Continuous UseAnnals of Pharmacotherapy, 1995
- Transdermal Delivery of Narcotic Analgesics: Comparative Metabolism and Permeability of Human Cadaver Skin and Hairless Mouse SkinJournal of Pharmaceutical Sciences, 1994
- System functionality and physicochemical model of fentanyl transdermal systemJournal of Pain and Symptom Management, 1992
- Transdermal fentanyl: Clinical pharmacologyJournal of Pain and Symptom Management, 1992
- Transdermal Delivery of Narcotic Analgesics: pH, Anatomical, and Subject Influences on Cutaneous Permeability of Fentanyl and SufentanilPharmaceutical Research, 1990
- The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effectsPain, 1989
- Transdermal Delivery of Narcotic Analgesics: Comparative Permeabilities of Narcotic Analgesics Through Human Cadaver SkinPharmaceutical Research, 1989